Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 19, 2026 [1] Core Insights - 2025 marked a significant year for Chinese innovative drugs going global, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs. The trend continues into 2026, with notable licensing agreements from companies like Yilian Biotech and Rongchang Biotech, indicating strong global competitiveness for Chinese innovative drugs [2] - Major companies are increasingly investing in the small nucleic acid field, with significant acquisitions and clinical approvals. For instance, China National Pharmaceutical Group acquired Hangzhou Hejiya Biopharmaceutical for 1.2 billion RMB, while international firms like Novartis and GSK are also advancing in this area [3] - The GLP-1 market is expected to grow despite new pricing systems, with ongoing collaborations and new product launches anticipated in 2026. The market for GLP-1 drugs is projected to remain robust due to the large patient population for weight loss and diabetes [4] - The oral autoimmune drug market is gaining attention, with promising results from Takeda's new TYK2 inhibitor for psoriasis. Other domestic companies are also advancing in this space, exploring new targets for oral small molecules [5] - The brain-computer interface sector is poised for industrialization, with companies like Neuralink set to produce devices in 2026. Domestic advancements and regulatory support are enhancing the potential for this technology in medical applications [6] - The ZAP-X radiation therapy device is expected to capture a significant market share in China, with rapid growth projected in non-invasive tumor radiation treatment, driven by increasing clinical recognition and adoption [8] Summary by Sections Industry Trends - The pharmaceutical sector is witnessing a resurgence in interest towards innovative drugs, with a notable increase in the innovative drug index by 8.97% since early January 2026, outperforming the CSI 300 index by 6.77 percentage points [2] Company Recommendations - Recommended companies include: - **Yuekang Pharmaceutical** and **Sunshine Nuohua** in the small nucleic acid space - **Yahong Pharmaceutical** and **Yifang Biotechnology** in the autoimmune sector - **Zhongsheng Pharmaceutical** in the GLP-1 market - **Baiyang Pharmaceutical** for ZAP-X radiation therapy - **Meihao Medical** for brain-computer interface technology [10] Market Opportunities - The non-invasive tumor radiation treatment market is projected to grow from 27.2 billion RMB in 2018 to 59.4 billion RMB by 2024, with a compound annual growth rate of 13.9% [8]

Core Viewpoint - The company, Xi'an Dayi Group, is attempting to go public on the Hong Kong Stock Exchange after four years, despite facing significant financial challenges and market competition in the gamma knife segment of the radiation therapy market [1][2]. Company Overview - Xi'an Dayi Group holds a dominant position in the Chinese gamma knife market with a projected market share of 70% in 2024 [1]. - Despite its leading market position, the company's revenue has not improved compared to four years ago, and net losses have significantly increased [1][5]. - The company's core product, CybeRay, is the first gamma radiation therapy device approved by both the Chinese National Medical Products Administration and the U.S. FDA [3]. Financial Performance - The company's revenue for 2023 and 2024 is projected to be 261 million yuan and 264 million yuan, respectively, which is a decline from previous years [5]. - The net losses for 2023 and 2024 are expected to be 69.78 million yuan and 94.57 million yuan, respectively, indicating a worsening financial situation [5]. - Research and development expenses are a significant factor in the company's losses, with 97.88 million yuan and 113 million yuan allocated for 2023 and 2024 [5]. Market Dynamics - The global radiation surgery market is expected to grow from $92.4 billion in 2024 to $138.9 billion by 2030, with the Chinese market projected to increase from 594 billion yuan to 1,058 billion yuan [2]. - The gamma knife market in China is expected to grow from 300 million yuan in 2024 to 500 million yuan by 2030, with a compound annual growth rate of 11.0% [3]. - In contrast, the integrated radiation therapy equipment market is expected to grow from 1.8 billion yuan in 2024 to 9.5 billion yuan by 2030, with a much higher compound annual growth rate of 31.5% [3]. Competitive Landscape - Despite being a leader in the gamma knife segment, the company only holds a 4.7% share of the overall radiation therapy equipment market in China, lagging behind international giants like Varian and local competitors [4]. - The number of gamma knives in China is significantly lower than linear accelerators, with only 296 gamma knives compared to 3,405 linear accelerators as of the end of 2020 [4]. Investment and Financing - The company has completed seven rounds of financing, raising a total of 1.571 billion yuan, with notable investors including Hillhouse Capital and Changchun Municipal Finance Bureau [1][7]. - The company faces pressure from investors due to the potential failure of its IPO, which could trigger buyback obligations under existing agreements [2][10].